Catalent (NYSE:CTLT) Price Target Cut to $58.00
Catalent (NYSE:CTLT) Price Target Cut to $58.00
Catalent (NYSE:CTLT – Get Rating) had its target price lowered by Barclays from $62.00 to $58.00 in a report released on Tuesday, The Fly reports. The brokerage currently has an "overweight" rating on the stock. Barclays's price target would suggest a potential upside of 15.63% from the company's previous close.
据The Fly报道,在周二发布的一份报告中,巴克莱将Catalent(NYSE:CTLT-GET Rating)的目标价从62.00美元下调至58.00美元。该券商目前对该股的评级为“增持”。巴克莱的目标股价显示,该公司较前一交易日收盘价有15.63%的潜在上行空间。
Other research analysts have also issued reports about the stock. Argus lowered shares of Catalent from a "buy" rating to a "hold" rating in a research note on Monday, November 7th. Robert W. Baird decreased their price objective on shares of Catalent from $123.00 to $75.00 in a report on Wednesday, November 2nd. TheStreet downgraded shares of Catalent from a "b-" rating to a "c+" rating in a report on Friday, October 28th. Morgan Stanley decreased their price objective on shares of Catalent from $120.00 to $81.00 and set an "overweight" rating on the stock in a report on Thursday, November 3rd. Finally, KeyCorp decreased their price objective on shares of Catalent from $125.00 to $85.00 and set an "overweight" rating on the stock in a report on Wednesday, November 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $92.40.
其他研究分析师也发布了有关该股的报告。Argus在11月7日星期一的一份研究报告中将Catalent的股票评级从“买入”下调至“持有”。罗伯特·W·贝尔德在11月2日星期三的一份报告中将加泰罗兰的股票目标价从123.00美元下调至75美元。华尔街在10月28日星期五的一份报告中将Catalent的股票评级从“b-”下调至“c+”。摩根士丹利在11月3日周四的一份报告中将卡特伦特股票的目标价从120.00美元下调至81.00美元,并对该股设定了“增持”评级。最后,KeyCorp在11月2日(星期三)的一份报告中将Catalent的股票目标价从125.00美元下调至85美元,并对该股设定了“增持”评级。一位研究分析师对该股的评级为卖出,三位分析师给出了持有评级,五位分析师给出了该公司股票的买入评级。根据MarketBeat.com的数据,该公司目前的普遍评级为持有,平均目标价为92.40美元。
Catalent Trading Up 1.2 %
Catalent交易上涨1.2%
Shares of Catalent stock opened at $50.16 on Tuesday. Catalent has a 52-week low of $40.69 and a 52-week high of $115.33. The company has a quick ratio of 2.08, a current ratio of 2.86 and a debt-to-equity ratio of 0.87. The company's 50-day simple moving average is $46.33 and its 200-day simple moving average is $71.89. The firm has a market cap of $9.03 billion, a price-to-earnings ratio of 21.44, a price-to-earnings-growth ratio of 3.63 and a beta of 1.24.
周二,Catalent的股票开盘报50.16美元。卡特伦特的52周低点为40.69美元,52周高位为115.33美元。该公司的速动比率为2.08,流动比率为2.86,债务权益比为0.87。该公司50日简单移动均线切入位在46.33美元,200日简单移动均线切入位在71.89美元。该公司的市值为90.3亿美元,市盈率为21.44倍,市盈率为3.63倍,贝塔系数为1.24。
Insider Buying and Selling at Catalent
Catalent的内幕买卖
In related news, insider Manja Boerman sold 780 shares of the company's stock in a transaction that occurred on Monday, December 5th. The shares were sold at an average price of $51.70, for a total transaction of $40,326.00. Following the transaction, the insider now owns 15,860 shares of the company's stock, valued at $819,962. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Manja Boerman sold 780 shares of the company's stock in a transaction that occurred on Monday, December 5th. The shares were sold at an average price of $51.70, for a total transaction of $40,326.00. Following the transaction, the insider now owns 15,860 shares of the company's stock, valued at $819,962. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael J. Grippo sold 2,451 shares of the company's stock in a transaction that occurred on Monday, October 31st. The shares were sold at an average price of $65.83, for a total transaction of $161,349.33. Following the transaction, the senior vice president now directly owns 17,792 shares in the company, valued at approximately $1,171,247.36. The disclosure for this sale can be found here. Insiders have sold 3,874 shares of company stock valued at $233,414 over the last quarter. Corporate insiders own 0.58% of the company's stock.
在相关新闻中,内部人士Manja Boerman在12月5日星期一的一笔交易中出售了780股该公司股票。这些股票的平均价格为51.70美元,总成交金额为40,326.00美元。交易完成后,这位内部人士现在拥有15,860股该公司股票,价值819,962美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过这个环节。在相关新闻中,内部人士Manja Boerman在12月5日星期一的一笔交易中出售了780股该公司股票。这些股票的平均价格为51.70美元,总成交金额为40,326.00美元。交易完成后,这位内部人士现在拥有15,860股该公司股票,价值819,962美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过这个环节。此外,高级副总裁迈克尔·J·格里波在10月31日星期一的一次交易中出售了2451股该公司股票。这些股票的平均价格为65.83美元,总成交金额为161,349.33美元。交易完成后,高级副总裁现在直接持有该公司17,792股股份,价值约1,171,247.36美元。关于这次销售的披露可以找到这里。在上个季度,内部人士已经出售了3874股公司股票,价值233,414美元。企业内部人士持有该公司0.58%的股份。
Hedge Funds Weigh In On Catalent
对冲基金对Catalent持股
Institutional investors and hedge funds have recently bought and sold shares of the stock. Bellevue Group AG acquired a new position in Catalent during the third quarter worth approximately $34,000. CX Institutional acquired a new position in Catalent during the second quarter worth approximately $37,000. Clear Street Markets LLC increased its position in Catalent by 408.1% during the second quarter. Clear Street Markets LLC now owns 376 shares of the company's stock worth $40,000 after purchasing an additional 302 shares during the last quarter. Motco acquired a new position in Catalent during the third quarter worth approximately $41,000. Finally, Alta Advisers Ltd acquired a new position in Catalent during the third quarter worth approximately $43,000. Institutional investors and hedge funds own 99.38% of the company's stock.
机构投资者和对冲基金最近买卖了该股的股票。Bellevue Group AG在第三季度收购了Catalent的一个新头寸,价值约3.4万美元。CX机构在第二季度收购了Catalent的一个新头寸,价值约3.7万美元。Clear Street Markets LLC在第二季度将其在卡特伦特的头寸增加了408.1%。Clear Street Markets LLC在上个季度又购买了302股,现在拥有376股该公司股票,价值40,000美元。Motco在第三季度收购了Catalent的一个新头寸,价值约41,000美元。最后,Alta Advisers Ltd在第三季度收购了加泰罗尼亚的一个新头寸,价值约43,000美元。机构投资者和对冲基金持有该公司99.38%的股票。
About Catalent
关于Catalent
(Get Rating)
(获取评级)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Catalent公司及其子公司在全球范围内开发和制造药物、基于蛋白质的生物制剂、细胞和基因疗法以及消费者保健产品的解决方案。软凝胶和口腔技术部门提供用于一系列客户产品的软胶囊的配方、开发和制造服务,如处方药、非处方药、膳食补充剂、单位剂量化妆品和动物保健药物制剂。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- 免费获取StockNews.com关于Catalent的研究报告(CTLT)
- AMD仍是市面上最好的半导体股票之一
- 两大股利大王:强生还是雅培?
- 网络安全类股已经见底了吗?
- 联合太平洋,诺福克南方进入购买区
- 柔顺治疗公司的差距增加了34%:未来还会有更多的好处吗?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Catalent Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Catalent和相关公司的最新新闻和分析师评级的每日简要摘要。